Asian literature

NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024

Retrieved on: 
月曜日, 6月 3, 2024
MD, Cancer, Toxicity, NK, Patient, Asian literature, Pharmaceutical industry

Song, MD, Chairman and Chief Executive Officer of NKGen Biotech, will present details on their cryopreserved allogeneic NK cell therapy platform as well as updated Phase 1 data on its use in solid tumors without lymphodepletion at the 6th Annual Allogeneic Cell Therapies Summit to be held in Boston, MA, from June 10-12, 2024.

Key Points: 
  • Song, MD, Chairman and Chief Executive Officer of NKGen Biotech, will present details on their cryopreserved allogeneic NK cell therapy platform as well as updated Phase 1 data on its use in solid tumors without lymphodepletion at the 6th Annual Allogeneic Cell Therapies Summit to be held in Boston, MA, from June 10-12, 2024.
  • Dr. Song’s presentation will detail the Company’s novel allogeneic blood-derived NK cell therapy (“SNK02”) commercial manufacturing and cryopreservation process, as well provide an update on their initial Phase 1 results using SNK02 to treat patients with advanced refractory solid tumors.
  • Furthermore, Dr. Song will explore the potential benefits of eliminating pre-treatment lymphodepletion in patients undergoing SNK02 therapy, aiming to safeguard immune function and aid in recovery.
  • Previously disclosed Phase 1 data on the positive effects of SNK02 on advanced solid tumors, which may not be included in this conference presentation, can also be found on the Scientific Publications page.

OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology

Retrieved on: 
月曜日, 6月 3, 2024
Research, Infectious Diseases, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Hook effect, Multimedia, Light, Journal, Molecular biology, Engineering, Immunology, Immunoglobulin G, Chicken, Asian literature, Vertebrate, Vaccine

OmniAb, Inc. (NASDAQ: OABI) today announced the publication of a peer-reviewed paper titled “Chickens with a Truncated Light Chain Transgene Express Single-Domain H Chain-Only Antibodies” in the Journal of Immunology demonstrating that chickens can be genetically engineered to produce functional heavy chain-only single-domain antibodies.

Key Points: 
  • OmniAb, Inc. (NASDAQ: OABI) today announced the publication of a peer-reviewed paper titled “Chickens with a Truncated Light Chain Transgene Express Single-Domain H Chain-Only Antibodies” in the Journal of Immunology demonstrating that chickens can be genetically engineered to produce functional heavy chain-only single-domain antibodies.
  • This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20240603162111/en/
    Image rendering of OmniAb’s OmnidAb™, a stabilized fully human heavy chain only single domain antibody (Graphic: Business Wire)
    sdAbs are produced naturally by camelids and have gained popularity as small, robust and highly modular building blocks for antibody discovery.
  • “Our team’s published data provided the foundational work supporting the feasibility of the Company’s next-generation transgenic chicken OmnidAb that produces fully human stabilized sdAbs.

ICH M14 guideline on general principles on plan, design and analysis of pharmacoepidemiological studies that utilize real-world data for safety assessment of medicines Step 2b

Retrieved on: 
日曜日, 6月 2, 2024
Consensus, Sentinel, Real-World Evidence, NPV, Privacy, Smoking, Business analyst, Interest, Scope, Section 3, Missing data, Attention deficit hyperactivity disorder, World Health Organization, Thrombosis, Vaccination, Artificial intelligence, GVP, Element, ICD-10, ICD, Target, Clutch (eggs), MedDRA, Anaphylaxis, Data collection, Multi, Registry, Infant, International Society, Collection, Incidence, Clinical study design, FD, Replication (computing), Deference, Failure, CDM, Innovation Center station, Prevalence, Diagnosis, Mortality, Pregnancy, Person, Data analysis, Classification, Committee, Knowledge, Silver, PMID, Development, Roger Hawkins (drummer), Record, Len Bias, 1113, Polypharmacy, Sensitivity analysis, Protocol, Risk, European Medicines Agency, FDA, Real, Joint, Step, Quality control, Documentation, Standard of care, Health care, Accident, Checklist, Database, Birth weight, Statistics, Communication, Natural language processing, Table, Data Governance Act, Common data model, Study, Reproduction, Quality assurance, European, BMJ, Quality, Conducting, Comorbidity, NMPA, Knowledge Organization (journal), Drug development, DHT, Conceptual, ISPE, Adrenaline, Marketing, Cancer, EHR, Phenotype, Safety, Rehabilitation, Research design, HCPCS, Treatment, Allergy, Electronic health record, Validity, Death, MAH, Quality of life, 1128, Confidentiality, Selection bias, Prescription, Machine learning, Duration, CIOMS, Vaccine, ICMJE, Injury, Workplace, Section 5, National Cancer Institute, Bangladesh Technical Education Board, Interval (mathematics), Regulation, Data quality, Management, GCP, Digital, Software, Meta-analysis, SNOMED, Section 8, Use, Biology, QC, Uncertainty, Birth defect, PPV, FDN, Publication bias, Draft, Shareware, Frailty, Disulfiram-like drug, Guideline, Publishing, Gestational diabetes, De novo, Big data, Conduct, Medication, Bias, Immunodeficiency, EMA, Social media, International Classification of Diseases, History, Name, Data management, M10, Algorithm, Ageing, Natural history, SAP, Asian literature, Disability, QA/QC, Immortal, NDC, Book, Human voice, Central Statistics Office (India), Content, Birth, Frontiers Media, Metadata, RxNorm, Data governance, GPP, Structuring, Radiology, Benzodiazepine, Lash, User experience, Theft, Methodology, Objective, RWD, COMMUNICATION, DATA, Literature, Health information management, Clinical trial, Dependent and independent variables, Research, Patient, ATC, INTRODUCTION, TB, Section 13, Contraindication, Insurance, Concomitant, Data, Index, M14, Gestational age, Data curation, Biomarker, ICH, Paper, CHMP, Medical device
Key Points: 

    DBV Technologies to Participate in Upcoming EAACI 2024 Congress

    Retrieved on: 
    木曜日, 5月 30, 2024
    Asian literature, Risk, Erasmus University Rotterdam, Congress, Peanut allergy, F10, Safety, DBV, Teaching hospital, DBV Technologies, Food, Allergy, Division, Poster, Immunotherapy, Geneva University Hospitals

    DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced its upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress May 31 – June 3 in Valencia, Spain.

    Key Points: 
    • DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced its upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress May 31 – June 3 in Valencia, Spain.
    • DBV will also host a symposium and exhibit booth in the EAACI exhibit hall.
    • “Reactions Due to Accidental Peanut Consumption During Epicutaneous Immunotherapy for Peanut Allergy in Toddlers” presented by Nicolette Arends, M.D.
    • Researcher, Pediatrics Erasmus University Medical Center, Rotterdam, Netherlands
      A voice-recording of the onsite flash talk presentation will be made available on the congress platform.

    Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models

    Retrieved on: 
    火曜日, 5月 21, 2024
    Asian literature, IBD, DDW, Disease, Patient, Inflammation, UC, PDE4, Toxicity, DAI, BID, Trial of the century, DSS, AUC, Apremilast, Mouse, Vomiting, Psoriasis, CMO, Internal bleeding, Autoimmunity, Poster, Human body weight, Therapy, Dog, Model, Drinking water, Pharmaceutical industry

    The poster is available on the Scientific Publications page of the Company’s website .

    Key Points: 
    • The poster is available on the Scientific Publications page of the Company’s website .
    • PALI-2108 demonstrates similar target engagement to the PDE4 inhibitor, apremilast, which is approved for use in psoriasis and psoriatic arthritis.
    • Importantly, PALI-2108 exhibited a dose-dependent efficacy response in two DSS colitis mouse models, achieving efficacy comparable to doses of apremilast considered intolerable for human use in UC patients.
    • No systemic toxicity in dogs and large therapeutic window due to local activation.

    OmniAb Presents High-Throughput Single B-cell Screening xPloration® Data at the 20th Annual PEGS Boston Summit

    Retrieved on: 
    水曜日, 5月 15, 2024
    Biotechnology, Technology, Other Health, Health, General Health, Pharmaceutical, Other Science, Other Technology, Research, Artificial Intelligence, Science, Asian literature, Amino acid, Boston, Machine learning, Omni Hotels & Resorts, Artificial intelligence, AI, Animal, Cell, Monoclonal antibody, Multimedia, Antibody, Biology, Vaccine

    OmniAb, Inc. (Nasdaq: OABI) today announced its participation in the 20th Annual PEGS Boston – The Essential Protein & Antibody Engineering Summit underway at the Omni Hotel.

    Key Points: 
    • OmniAb, Inc. (Nasdaq: OABI) today announced its participation in the 20th Annual PEGS Boston – The Essential Protein & Antibody Engineering Summit underway at the Omni Hotel.
    • “The synergy between xPloration, OmniFlic, OmniClic, and OmniDeep enables new bispecific antibody discovery workflows for our partners.
    • With xPloration, OmniAb’s scientific team screened tens of millions of cells and recovered thousands of unique antibody sequences.
    • For more information about OmniAb’s proprietary technologies, please visit www.omniab.com or contact our business development team at [email protected] .

    Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress

    Retrieved on: 
    水曜日, 5月 8, 2024
    Mutation, Safety, Pembrolizumab, Research, Asian literature, CRC, RAS, SHP2, Initiation, Trial of the century, Disclosure, PDAC, BRAF, Patient, SOC, Neoplasm, NRAS, AACR, Clinical trial, Sanofi, G13, GAAP, Lung cancer, Pharmaceutical industry

    REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2024, and provided an update on corporate progress.

    Key Points: 
    • REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2024, and provided an update on corporate progress.
    • The company continues making progress on its 2024 development priorities:
      Advancing its RAS(ON) multi-selective inhibitor RMC-6236 into monotherapy pivotal trials.
    • Revenue: Total revenue was zero for the quarter ended March 31, 2024, compared to $7.0 million for the quarter ended March 31, 2023.
    • Revolution Medicines will host a webcast this afternoon, May 8, 2024, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).

    Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

    Retrieved on: 
    水曜日, 4月 24, 2024
    University, CRISPR, Rachel Haurwitz, Abstract (summary), Abstract, Asian literature, Huntsman Cancer Institute, Amplification, Leukemia, ASCO, Lymphoma, CLL, Society, CDT, MD Anderson Cancer Center, Annual general meeting

    BERKELEY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts have been accepted for poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31-June 4, 2024 in Chicago, Illinois.

    Key Points: 
    • BERKELEY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts have been accepted for poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31-June 4, 2024 in Chicago, Illinois.
    • The ANTLER poster will provide initial dose expansion data.
    • Details of the poster presentation are as follows:
      Presenter: Boyu Hu, MD, assistant professor, director of lymphoma and CLL, division of hematology/hematologic malignancies, Huntsman Cancer Institute at the University of Utah
      The AMpLify poster will provide details on the clinical trial design and objectives.
    • Poster presentations will be available on the Scientific Publications page of Caribou’s website on Monday, June 3, 2024 at 9:00 am CDT.

    NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit

    Retrieved on: 
    木曜日, 4月 18, 2024
    Amyloid, Neurodegenerative disease, Asian literature, MD, Patient, Biomarker, NK, Pharmaceutical industry

    SANTA ANA, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced that Paul Y.

    Key Points: 
    • SANTA ANA, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced that Paul Y.
    • Song, MD, Chairman and Chief Executive Officer of NKGen Biotech, will present details around its NK cell therapy in neurodegenerative disease, review its preclinical data in Parkinson’s disease, and highlight clinical safety and efficacy data from the Company’s recently completed Phase 1 clinical trial of SNK01, autologous natural killer cell therapy, in Alzheimer’s disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit to be held in Boston, MA, from April 23–25, 2024.
    • Dr. Song will also present clinical safety and efficacy data from the Company’s recently completed Phase 1 clinical trial evaluating autologous SNK01 NK cell therapy in patients with Alzheimer’s disease (NCT04678453).
    • A copy of the presentation will be available on the Scientific Publications page of the Company’s website at https://nkgenbiotech.com/ once the presentation has concluded.

    Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

    Retrieved on: 
    月曜日, 4月 15, 2024
    CRISPR, Rachel Haurwitz, Abstract, Asian literature, Cas12a, Cell, Gene, Society

    BERKELEY, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an abstract on the efficient use of Cas12a chRDNA genome-editing technology for in vivo hepatic gene disruption has been accepted for an oral presentation at the 27th annual meeting of the American Society of Gene and Cell Therapy (ASGCT), which is being held May 7-11, 2024, in Baltimore, Maryland.

    Key Points: 
    • BERKELEY, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an abstract on the efficient use of Cas12a chRDNA genome-editing technology for in vivo hepatic gene disruption has been accepted for an oral presentation at the 27th annual meeting of the American Society of Gene and Cell Therapy (ASGCT), which is being held May 7-11, 2024, in Baltimore, Maryland.
    • Details of the oral presentation are as follows:
      Accepted abstracts will be available on the ASGCT Annual Meeting website on April 22, 2024 at 4:30 pm ET.
    • The presentation will be available on the Scientific Publications page of Caribou’s website on Friday, May 10, 2024 at 6:00 am ET.